A phase 2 clinical trial of talazoparib, a PARPi, and avelumab, an ICI, demonstrated limited antitumor activity (ORR of 0%, median PFS 3.5 months) in a cohort of 10 patients with VHL-altered advanced ccRCC.95 Several studies are currently investigating the relevance of PARPi in treating advanced RCC. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.